Stockwatch: No Earnings Disappointments Are The New Black
Executive Summary
As the first-quarter 2016 earnings season got underway for life science companies last week expectations were not high. In the event the first week of announcements was not as bad as many had feared. The stock market typically over-reacts to both good and bad news so in the absence of a wholesale missing of analysts' consensus estimates, by Thursday April 21, the market had gotten a little ahead of itself.
You may also be interested in...
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
Move over Zarxio. There's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a while before patients have access to the new drug, since Celltrion Inc. and Pfizer Inc. said they won't put it on the market until after June 29.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.